An Open-Label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen.

Next Previous
Trial Profile

An Open-Label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2014

At a glance

  • Drugs Belatacept (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Feb 2012 Planned end date changed from 1 Aug 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 20 Oct 2008 Basic check conducted, last updated 26-09-2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top